Drug Channels

MARCH 4, 2025

for an exclusive deep dive into the latest trends, data, and strategies shaping the pharmacy benefit management (PBM) industry. Pharmacies and Pharmacy Benefit Managers , Dr. Fein will provide invaluable insights to help you and your team stay informed about this rapidly evolving market. Fein, Ph.D.,

Pharmacy 98

Pharmacy Specialty Pharmacies Marketing Drugs 98

Fierce BioTech

DECEMBER 23, 2024

and often require consistent batches of drug product be administered to groups of research participants within a short timeframe, early phase studies present unique challenges for drug developers not typically experienced in later stages of development. First-in-Human, Drug-Drug Interaction, Food Effect, Bioequivalence, etc.),

Pharmacy 52

Pharmacy Trials Clinical Trials Clinical Development 52

Drug Channels

JUNE 18, 2024

See The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents. In DCI’s exclusive analysis below, we show that specialty pharmacies affiliated with pharmacy benefit managers (PBMs) play an outsized role in manufacturer-designated dispensing networks.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Drugs Production 52

Drug Channels

OCTOBER 21, 2024

Informa Connect’s Trade and Channel Strategies December 10-12, 2024 at the W Hotel in Philadelphia, PA Drug Channels readers save 10% with code 24DC10 * Pharmacy and distribution models are growing increasingly complex. Is my organization haemorrhaging money to stay afloat with the shift to alternative distribution and pharmacy models?

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Marketing Compliance 98

Perficient: Drug Development

JANUARY 23, 2024

Is there anything worse than going to a pharmacy to pick up your prescriptions? Thankfully, many pharmacies have adopted home delivery services. Here are three ways pharmacies can adopt this Adobe Commerce solution to extend and secure trust with their patients. However, this presents some challenges.

Pharmacy 52

Pharmacy Doctors Production Science 52

Drug Channels

APRIL 24, 2024

See The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents. In DCI’s exclusive analysis below, we show that specialty pharmacies affiliated with pharmacy benefit managers (PBMs) play an outsized role in manufacturer-designated dispensing networks.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Production Drugs 52

FDA Law Blog: Biosimilars

AUGUST 21, 2023

Attorney’s Office for the Western District of Texas announced that People’s Rx, a local chain operating five retail pharmacies and a compounding laboratory in the Austin area, agreed to pay $200,000 to settle allegations that it violated the Controlled Substances Act (“CSA”). 16, 2023 ( DOJ Press Release ). 2, 2020 ( DOJ Press Release ).

Pharmacy 52

Pharmacy Regulations Production Laboratories 52

Drug Channels

SEPTEMBER 23, 2020

Will COVID-19 trigger long-term share gains for specialty pharmacies as suppliers to hospitals and physician offices? Before the pandemic, specialty pharmacies—via white, brown, and clear bagging—had already displaced buy-and-bill distribution channels for a substantial chunk of provider-administered specialty drugs.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Hospitals Production 52

Drug Channels

JULY 18, 2023

As I predicted in 2021 , some products launched with list prices that are only slightly lower than Humira’s list price, while others are trying to tempt payers and pharmacy benefit manages (PBMs) with deep list price discounts. This month, nine biosimilar versions of adalimumab launched in the U.S.

Biosimilars 98

Biosimilars Pharmacy Marketing Drugs 98

Drug Channels

APRIL 16, 2021

To learn more about AssistRx’s technology solutions register for their Optimizing Program Performance: An Innovative Approach for Retail and Specialty Products webinar series. Read on for Jeff’s insights. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Production 52

Production Pharmacy Therapies Drugs 52

Drug Channels

DECEMBER 18, 2020

Will COVID-19 trigger long-term share gains for specialty pharmacies as suppliers to hospitals and physician offices? Before the pandemic, specialty pharmacies—via white, brown, and clear bagging—had already displaced buy-and-bill distribution channels for a substantial chunk of provider-administered specialty drugs.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Hospitals Drugs 52

Drug Channels

SEPTEMBER 2, 2020

I'm rerunning this post to provide context for manufacturers' recent actions regarding 340B contract pharmacies. Yesterday, Eli Lilly announced that its products can be dispensed only at covered entities and their child sites, but not via external pharmacies. per 3 mL pen or $0.10 per 10 mL vial.

Pharmacy 52

Pharmacy Government Hospitals Pharmaceuticals 52

Drug Channels

MARCH 28, 2023

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Each exclusion list now contains about 600 products. Click here to see the original post and comments from January 2023.

Biosimilars 98

Biosimilars Pharmacy Drugs Production 98

Drug Channels

OCTOBER 3, 2023

As I predicted in 2021 , some products launched with list prices that are only slightly lower than Humira’s list price, while others are trying to tempt payers and pharmacy benefit managers (PBMs) with deep list price discounts. This month, nine biosimilar versions of adalimumab launched in the U.S.

Biosimilars 98

Biosimilars Pharmacy Marketing Pharmaceuticals 98

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. Today’s guest post comes from Saket Patel, Consultant, Advisory Services at MMIT. He then describes how to automate formulary and medical policies to protect manufacturers from overpayment.

Biosimilars 97

Biosimilars Pharmacy Therapies Production 97

Drug Channels

MARCH 5, 2024

WHAT YOU WILL LEARN In 2023, the Inflation Reduction Act of 2022 (IRA) began to alter the Medicare Part D program and trigger changes in beneficiary out-of-pocket spending, drug prices, pharmacy economics, and market access strategies. Pharmacies and Pharmacy Benefit Managers.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98

Drug Channels

JUNE 9, 2023

Today’s guest post comes from Kristina Crockett, VP, Product Management at CoverMyMeds. Kristina shares the story of Shanette, a single mother who faced sticker shock at the pharmacy counter. Kristina then explains how manufacturers can increase patient access and affordability with a comprehensive affordability strategy.

Pharmacy 98

Pharmacy Production Drugs 98

The Pharma Data

JULY 29, 2021

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product approved in the U.S.

Biosimilars 52

Biosimilars Production FDA Approval FDA 52

Drug Channels

OCTOBER 20, 2023

Today’s guest post comes from Melanie Christie, VP of Product Management at CoverMyMeds. Melanie discusses how the nationwide shortage of pharmacy technicians affects pharmacists.

Pharmacy 98

Pharmacy Treatment Production Drugs 98

Drug Channels

SEPTEMBER 22, 2023

Today’s guest post comes from Kristina Crockett, VP of Product Management at CoverMyMeds. In this article, Kristina reviews how brands can help patients make connections that address medication affordability challenges, whether at the prescriber’s office, the pharmacy, or at home. Read on for Kristina’s insights.

Pharmacy 98

Pharmacy Production Drugs 98

Drug Channels

SEPTEMBER 22, 2023

Today’s guest post comes from Kristina Crockett, VP of Product Management at CoverMyMeds. In this article, Kristina reviews how brands can help patients make connections that address medication affordability challenges, whether at the prescriber’s office, the pharmacy, or at home. Read on for Kristina’s insights.

Pharmacy 97

Pharmacy Production Drugs 97

Advarra

AUGUST 31, 2022

Institutional biosafety committees (IBCs) frequently receive questions about the proper methodology for preparing a syringe for transport from a drug room or pharmacy to the clinic where the injection will be administered. The post Safe Sharps Handling When Dispensing Investigational Products appeared first on Advarra.

Production 52

Production Engineering Pharmacy Virus 52

Drug Target Review

FEBRUARY 10, 2025

Over the years, Ive had the privilege of working on more than 25 different products, Bock shared. In this model, once a product is produced and delivered to the clinical pharmacy, the clinical team takes over the trial with little to no interaction with the manufacturing team.

Therapies 64

Therapies Treatment Engineering Clinical Trials 64

Drug Channels

FEBRUARY 23, 2021

In this issue: Payers confess: Patients lose from copay accumulators Humana joins the Express Scripts GPO Hospitals vs. PBMs over specialty pharmacy white bagging Let’s all follow the Buy-and-Bill Dollar! Plus, entrepreneurial pharmacy owner Dave Marley demonstrates the power of innovation. See page 15 (reproduced below). million.

Pharmacy 52

Pharmacy Specialty Pharmacies Hospitals Independent Pharmacies 52

Drug Channels

JANUARY 19, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Each exclusion list contains 400 to 500 products.

Biosimilars 98

Biosimilars Pharmacy Drugs Production 98

Drug Channels

JANUARY 10, 2023

For 2023, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again increased the number of drugs they exclude from their standard formularies. Each exclusion list now contains about 600 products.

Biosimilars 98

Biosimilars Pharmacy Drugs Production 98

Advarra

OCTOBER 26, 2023

Ensuring the safe and secure transport of investigational products (IP) is a core part of biosafety. This critical task requires meticulous planning and rigorous procedures to avoid any hazards potentially arising during the journey of an IP from the controlled environment of a pharmacy or preparation room to its destination.

Production 52

Production Pharmacy Clinical Trials Engineering 52

Drug Channels

JANUARY 16, 2024

As I explain, this growth will challenge payer and channel economics, while boosting profits for patient reimbursement hub businesses and pharmacy benefit managers (PBMs). The widespread use of these products will also lead to greater scrutiny of utilization management—the tools that PBMs use to influence and manage prescription costs.

Pharmacy 98

Pharmacy Drugs Production 98

Drug Channels

JANUARY 9, 2024

For 2024, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again each excluded 600 or more drugs from their standard formularies. You can find our updated counting below. Read on for my deep dive into these two therapeutic categories.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Channels

APRIL 20, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Each exclusion list contains 400 to 500 products.

Biosimilars 98

Biosimilars Pharmacy Drugs Production 98

Drug Channels

OCTOBER 23, 2023

With regulation and policy changes, specifically surrounding the DCSCA, IRA and serialization, the loss of exclusivity wave, adoption of low-WAC products affecting GTN and the rise of alternative distribution models, there has never been a more important time for industry to unite. How is health policy affecting the distribution channel?

Pharmacy 75

Pharmacy Biosimilars Marketing Production 75

Drug Channels

SEPTEMBER 13, 2023

For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. Despite the concerted efforts of insurers such as UnitedHealthcare and Elevance Health, however, buy-and-bill remains the most common channel for these products.

Specialty Pharmacies 97

Specialty Pharmacies Pharmacy Pharmaceuticals Drugs 97

Alta Sciences

DECEMBER 14, 2023

A Closer Look At Our On-Site Compounding Pharmacies shajjar Thu, 12/14/2023 - 21:30 HTML Altasciences' dedicated pharmacists bring a wealth of expertise in controlled substances and complex compounding, ensuring maximum precision and safety standards. Electronic security access to the pharmacy and video monitoring. -

Compounding Pharmacies 40

Compounding Pharmacies Pharmacy Clinical Pharmacology Clinical Supply 40

Drug Channels

DECEMBER 13, 2023

For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. Despite the concerted efforts of insurers such as UnitedHealthcare and Elevance Health, however, buy-and-bill remains the most common channel for these products.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Pharmaceuticals Drugs 98

FDA Law Blog: Biosimilars

MAY 13, 2024

Extolling RWE, FDA has said “RWE can be leveraged to bring new products to market, evaluate the safety and effectiveness of existing products for new uses, and assess the continued performance and safety of products once on the market.”

FDA 111

FDA Production Trials Clinical Trials 111

Drug Channels

OCTOBER 17, 2022

Join your colleagues from across the industry and be part of critical, solution-focused discussions designed to help optimize distribution models and channel strategies driven by market dynamics, product types, site of care and reimbursement, all delivered by an expert speaking faculty.

Biosimilars 75

Biosimilars Pharmacy Therapies Production 75

Drug Channels

APRIL 19, 2021

Informa Connect’s Compliance Congress for Specialty Products. Up your compliance game at this important event serving the unique sector of Specialty Products, the 7th annual Virtual Compliance Congress for Specialty Products. June 22-24, 2021 | Virtual Event www.informaconnect.com/specialty-compliance/.

Compliance 40

Compliance Production Specialty Pharmacies Pharmaceutical Companies 40